Schizophrenia is a chronic and severe psychiatric disorder that has profound impact on an
individual's life and on society. Thus, developing more effective therapeutic interventions is …

Glutamate is the primary excitatory neurotransmitter in mammalian brain. Disturbances in
glutamate-mediated neurotransmission have been increasingly documented in a range of …

Schizophrenia is a devastating psychiatric illness that afflicts 1% of the population
worldwide, resulting in substantial impact to patients, their families, and health care delivery …

Glutamatergic neurotransmission, particularly through the N-methyl-d-aspartate (NMDA)
receptor, has drawn attention for its role in the pathophysiology of schizophrenia. This paper …

The NMDA-R hypofunction model of schizophrenia started with the clinical observation of
the precipitation of psychotic symptoms in patients with schizophrenia exposed to PCP or …

The Dopamine Hypothesis of Schizophrenia is actively being challenged by the NMDA
Receptor Hypofunctioning Hypothesis of Schizophrenia. The latter hypothesis may actually …

1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor,
schizophrenia remains a chronic, disabling disorder for most affected individuals. 2. Studies …

Early models for the etiology of schizophrenia focused on dopamine neurotransmission
because of the powerful anti‐psychotic action of dopamine antagonists. Nevertheless …

OBJECTIVE: Research has implicated dysfunction of glutamatergic neurotransmission in the
pathophysiology of schizophrenia. This review evaluates evidence from preclinical and …

Here, we describe our collaborative efforts to use N-methyl-d-aspartate (NMDA) receptor
antagonists as a translational tool to advance our understanding of the pathophysiology of …